Protagenic Therapeutics is a biopharmaceutical company based in New York, focusing on the development of therapeutics for neuropsychiatric and mood disorders caused by stress. The company's primary compound is PT00114, which is a synthetic form of teneurin carboxy-terminal-associated peptide, an endogenous brain signaling peptide that can help to reduce overactive stress responses. Protagenic Therapeutics is committed to finding effective treatments to alleviate the symptoms of stress-related conditions.